Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis

• Published in: International journal of molecular sciences Vol. 24; no. 12; p. 10199
• Main Authors: Mendoza-Torreblanca, Julieta Griselda, Cárdenas-Rodríguez, Noemi, Carro-Rodríguez, Jazmín, Contreras-García, Itzel Jatziri, Garciadiego-Cázares, David, Ortega-Cuellar, Daniel, Martínez-López, Valentín, Alfaro-Rodríguez, Alfonso, Evia-Ramírez, Alberto Nayib, Ignacio-Mejía, Iván, Vargas-Hernández, Marco Antonio, Bandala, Cindy
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.06.2023; MDPI
• Subjects: Adjuvant treatment; Adjuvants, Immunologic - therapeutic use; Agonists; Angiogenesis; Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; antiangiogenic; Antiangiogenics; Antimitotic agents; Antineoplastic agents; Arthritis; Blood vessels; Cancer; Clinical trials; Dehydrogenases; Dopamine; dopamine (DA); Dopamine - metabolism; dopamine agonists (DA-Ag); Dopamine Agonists - pharmacology; Dopamine D2 receptors; Endometriosis; Endometriosis - drug therapy; Endothelium; Enzymes; Female; Fenoldopam; Growth factors; Health aspects; Health services; Homeostasis; Humans; Monoclonal antibodies; Neoplasms - metabolism; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - metabolism; Nervous system; Oncology, Experimental; Osteoarthritis; osteoarthritis (OA); Osteoarthritis - drug therapy; Parkinson's disease; Permeability; Phenols; Phosphorylation; Physiology; Proteins; Restless legs syndrome; Review; Ropinirole; Schizophrenia; Signal transduction; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism; Vascular Endothelial Growth Factor Receptor-2 - metabolism; Vascular endothelial growth factor receptors; Mexico; dopamine agonists (DA-Ag); antiangiogenic; dopamine (DA); endometriosis; vascular endothelial growth factor (VEGF); cancer; osteoarthritis (OA); vascular endothelial growth factor receptor (VEGFR)
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms241210199

Dopamine (DA) and dopamine agonists (DA-Ag) have shown antiangiogenic potential through the vascular endothelial growth factor (VEGF) pathway. They inhibit VEGF and VEGF receptor 2 (VEGFR 2) functions through the dopamine receptor D2 (D2R), preventing important angiogenesis-related processes such as proliferation, migration, and vascular permeability. However, few studies have demonstrated the antiangiogenic mechanism and efficacy of DA and DA-Ag in diseases such as cancer, endometriosis, and osteoarthritis (OA). Therefore, the objective of this review was to describe the mechanisms of the antiangiogenic action of the DA-D2R/VEGF-VEGFR 2 system and to compile related findings from experimental studies and clinical trials on cancer, endometriosis, and OA. Advanced searches were performed in PubMed, Web of Science, SciFinder, ProQuest, EBSCO, Scopus, Science Direct, Google Scholar, PubChem, NCBI Bookshelf, DrugBank, livertox, and Clinical Trials. Articles explaining the antiangiogenic effect of DA and DA-Ag in research articles, meta-analyses, books, reviews, databases, and clinical trials were considered. DA and DA-Ag have an antiangiogenic effect that could reinforce the treatment of diseases that do not yet have a fully curative treatment, such as cancer, endometriosis, and OA. In addition, DA and DA-Ag could present advantages over other angiogenic inhibitors, such as monoclonal antibodies.